ByTrending Posts
Can Novo Nordisk and Fangzhou’s AI-Powered Partnership Reshape…
Key Insights: Revolutionizing Chronic Disease ManagementChina faces one of the world’s highest burdens of chronic diseases, particularly diabetes…
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma…
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven…
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between Tokyo-based Chugai Pharmaceutical…
Could AbbVie and IGI’s $1.9B Bet on AI-Engineered…
Key Highlights: AbbVie Accelerates into AI-Powered Immuno-OncologyAbbVie has entered a global licensing agreement worth up to $1.925 billion…
Can Personalis and Tempus Leverage AI to Transform…
Key Highlights AI at the Core of Next-Gen Recurrence MonitoringThe expansion of Personalis’ NeXT Personal® MRD test into…
Will AI-Powered Querent™ by Mango Sciences Transform Veeda…
Key Highlights AI-Driven Precision in Global Trial RecruitmentVeeda Lifesciences, a global CRO, has announced a strategic investment in…
Can Revolution Medicines and Iambic’s AI Alliance Accelerate…
Key Highlights AI-Powered Discovery for RAS-Addicted CancersRevolution Medicines, a leader in targeting RAS-driven cancers, is turning to artificial…
Can Johnson & Johnson’s 6-Point AI Strategy Revolutionize…
Key Highlights From Experimentation to Execution: Focused AI for Measurable OutcomesAfter piloting 900+ generative AI use cases, Johnson…
At VivaTech 2025, Can NVIDIA, Sanofi, and TetraScience…
Key Highlights The 20-Exabyte Problem: Data, Not Models, Is the Limiting FactorAt The Rise of Scientific AI panel…
Trending Posts
Latest Stories
Which AI Biopharma Startups Truly Won in 2025—And How Did NVIDIA, Big Pharma Collaborations, and Deal Value Define Success?
Executive Perspective 2025 marked a decisive shift for AI biopharma startups—from experimental promise to measurable…
Is Nabla Bio Redefining AI-Driven Protein Engineering as Pharma Seeks Faster Paths to Biologics Innovation?
Executive Summary Nabla Bio is emerging as a next-generation AI biotech focused on computationally driven…
Is AbCellera Biologics Building a Durable AI Antibody Discovery Engine as Pharma Partnerships Signal Multi-Billion-Dollar Potential?
Executive Summary AbCellera Biologics has established itself as a global leader in AI-driven antibody discovery,…
Is Recursion Pharmaceuticals Setting the Standard for AI-Powered Drug Discovery with Strategic Deals and a $20B+ Partnership Pipeline?
Executive Summary Recursion Pharmaceuticals has emerged as a leading clinical-stage TechBio company applying artificial intelligence,…
Gallery
